Phase I dose escalation and expansion study of PRAME T-cell receptor (TCR) engineered IL15-transduced cord blood–derived natural killer (NK) cells in patients with recurrent and/or refractory melanoma (PRAMETIME-Mel).

Authors: Derrick Law Tao, Reham Abdel-Wahab, Ruitao Lin, May Daher, Bin Liu, Rafet Basar, Elizabeth J. Shpall, Katy Rezvani, Adi Diab

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps9602

Source: Full article

TPS9602